Plain-English translation of NCT06613490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called KN5501, which consists of specially engineered immune cells designed to reduce harmful B cells in the body. Researchers believe this approach may help patients whose rheumatoid arthritis or antisynthetase syndrome has not improved with other medicines. You would receive three infusions of this medication over the course of the study.
Many patients with severe rheumatoid arthritis and antisynthetase syndrome don't respond well to current treatments, leaving them with ongoing pain, inflammation, and disability. This study explores whether this new type of engineered immune cell therapy could be a better option for these patients.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital three times to receive infusions of the engineered immune cells. Between infusions, your doctors will monitor how well the treatment is working and check for any side effects through blood tests and regular clinic visits. The trial will track how long these cells survive in your body and whether they successfully reduce the harmful B cells driving your disease over approximately 12 weeks or longer.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China